Most compounds in a research catalog share a common trait: their story is entirely preclinical, or it stalled somewhere in early human testing. SS-31 is the rare exception. In September 2025 its clinical-stage identity, elamipretide, became the first mitochondria-targeted peptide ever approved by the U.S. Food and Drug Administration — a milestone that took nearly two decades and a famously bumpy regulatory path to reach. But that approval is far narrower than the "mitochondrial health" language that tends to surround this molecule, and the gap between the two is the most useful thing a researcher can understand about it.
What SS-31 actually is
SS-31 is a Szeto–Schiller peptide — one of a family of short, cell-permeable, amphipathic tetrapeptides developed by Hazel Szeto and Peter Schiller at Weill Cornell in the early 2000s. Its sequence is D-Arg–2′,6′-dimethyltyrosine–Lys–Phe-NH₂: four residues, an alternating cationic–aromatic motif, and two deliberate departures from an ordinary peptide. The N-terminal arginine is the D-enantiomer, and the second residue is a methylated, non-standard tyrosine. Those modifications matter for two reasons — they make the peptide resistant to the peptidases that would rapidly shred a normal tetrapeptide, and they let it cross the plasma membrane and concentrate inside cells without a dedicated transporter.
That places SS-31 in a different structural class from most of the catalog. It is not a secretagogue, not a hormone analog, and — importantly — not an endogenous signaling peptide. It contrasts directly with MOTS-c, the mitochondrial-derived peptide the body encodes and secretes on its own. SS-31 is a synthetic, mitochondria-targeted molecule: engineered from scratch to go to one place and do one job.
The cardiolipin mechanism
That one place is the inner mitochondrial membrane, and the target is cardiolipin — an unusual anionic (negatively charged) phospholipid found almost exclusively in that membrane and nearly nowhere else in the cell. SS-31's alternating positive and aromatic residues give it a strong affinity for cardiolipin's negative surface charge, so the peptide partitions selectively into the inner membrane where cardiolipin is concentrated.
What it does once bound is where the science has genuinely shifted over the years. Early work described SS-31 as a mitochondrial antioxidant — a scavenger of reactive oxygen species. More recent biophysical studies, including work published in the Journal of Biological Chemistry in 2020, reframed it: rather than acting mainly as a free-radical sponge, SS-31 binds cardiolipin and modulates the surface electrostatics of the membrane, helping stabilize the folded cristae architecture, protect the organization of the electron-transport-chain complexes, and thereby improve the efficiency of ATP production while lowering the reactive oxygen species that leak from a poorly organized chain. The distinction is not academic. It moves the mechanism from "generic antioxidant" to "structural chaperone of the mitochondrial membrane" — a much more specific and testable claim.
From SS-31 to elamipretide to FORZINITY
The naming trail matters, because the same molecule travels under three labels. SS-31 is the original laboratory code name. Elamipretide is its International Nonproprietary Name, assigned once it entered formal drug development under Stealth BioTherapeutics, which built its program around the Szeto–Schiller chemistry. FORZINITY is the brand name under which the FDA-approved product is now sold. It is one tetrapeptide throughout; the label simply tells you which stage of its life you are looking at. (Older literature also refers to it as MTP-131 and Bendavia.)
The Barth syndrome approval
On September 19, 2025, the FDA granted accelerated approval to elamipretide to improve muscle strength in patients with Barth syndrome who weigh at least 30 kg — the first marketing authorization for the compound, and the first approved therapy for that disease. It is a once-daily subcutaneous injection given under medical supervision.
Barth syndrome is an almost poetically appropriate first indication, because it is fundamentally a cardiolipin disease. It is a rare, X-linked disorder caused by mutations in the TAFAZZIN (TAZ) gene, whose protein product is the enzyme that remodels newly made cardiolipin into its mature form. Without functional tafazzin, cells accumulate immature monolysocardiolipin and lose normal mature cardiolipin, destabilizing exactly the inner-membrane structure that SS-31 was designed to bind and support. A cardiolipin-targeting peptide meeting a cardiolipin-remodeling defect is about as clean a mechanistic rationale as rare-disease drug development offers.
The path there was not clean, though, and that is worth knowing. Development in Barth ran through the TAZPOWER trial and its long open-label extension. In an October 2024 briefing document, FDA reviewers wrote that they did not believe the available evidence established effectiveness. The agency's Cardiovascular and Renal Drugs Advisory Committee then voted 10 to 6 that the data did support effectiveness. Manufacturing-facility inspection issues and delays followed, and only in 2025 did the FDA identify a "path forward," using knee-extensor muscle strength as an intermediate endpoint to support accelerated approval. Accelerated approval means precisely that: the drug cleared the bar on a surrogate/intermediate measure judged reasonably likely to predict clinical benefit, with confirmatory obligations still ahead. It is an approval — but a conditional, narrowly scoped one.
Where the broader story is still unproven
The reason the "mitochondrial-health" framing outruns the evidence is that outside Barth syndrome, elamipretide's large controlled trials have mostly missed their primary endpoints.
- Primary mitochondrial myopathy — MMPOWER-3 (Neurology, 2023). This 218-participant Phase 3 trial randomized patients to subcutaneous elamipretide or placebo for 24 weeks and failed both co-primary endpoints — distance on the six-minute walk test and total fatigue on a symptom assessment. The drug was well tolerated, and a post-hoc subgroup carrying nuclear-DNA variants (including chronic progressive external ophthalmoplegia) showed an encouraging walk-distance signal, but the trial itself was negative and that subgroup finding is hypothesis-generating, not confirmatory.
- Dry age-related macular degeneration / geographic atrophy — ReCLAIM-2 (Ophthalmology Science, 2024). This 176-patient Phase 2 trial also missed its co-primary endpoints (low-luminance visual acuity and geographic-atrophy area). It reported signals worth following — on the order of a 43–47% relative reduction in the progression of ellipsoid-zone attenuation, and a low-luminance visual-acuity gain in a subset of completers — but those are secondary and exploratory outcomes.
Put together, the record is unusually instructive: one narrow accelerated approval built on a tight mechanistic match, sitting alongside well-run trials that came up short in the broader indications where a "mitochondrial energizer" would supposedly shine. That is a more honest and more interesting picture than either "approved wonder-drug" or "unproven research chemical" on its own.
Reading SS-31 as a research compound
For the laboratory research community, a few things follow. First, SS-31 remains a research-use-only compound in this catalog. The FORZINITY approval covers one specific rare disease under medical supervision and says nothing about the mitochondrial-fitness, exercise-recovery, or anti-aging framings that circulate informally. Those remain investigated in models, not established in people.
Second, SS-31 sits more firmly in the literature than several of its neighbors on the longevity shelf. Where Epithalon rests largely on a single research lineage, elamipretide has passed through multiple independent, multicenter, placebo-controlled human trials — which is precisely why we can speak so concretely about what it did and did not do.
Third, from a sourcing standpoint, the molecule's defining features create identity questions worth confirming on a certificate of analysis. Its D-arginine and dimethyltyrosine are non-standard residues; a synthesis that substituted ordinary L-arginine or plain tyrosine would yield a different — and likely inactive — tetrapeptide of nearly identical mass. That is exactly the kind of distinction mass spectrometry and orthogonal identity testing exist to catch, and a good reminder to read the quality documentation rather than the name on the vial.
FAQ
Is SS-31 the same thing as elamipretide? Yes. SS-31 is the laboratory code name, elamipretide is the drug-development (INN) name, and FORZINITY is the approved brand name — one Szeto–Schiller tetrapeptide throughout. Older papers also call it MTP-131 or Bendavia.
Is SS-31 an antioxidant? That was the early description, but the mechanism has been revised. Current biophysical work frames it primarily as a cardiolipin-binding, cristae-stabilizing peptide that improves electron-transport organization; the reduction in reactive oxygen species appears to be a downstream consequence rather than the main event.
Does the 2025 FDA approval mean SS-31 is proven for general "mitochondrial health"? No. The accelerated approval is limited to Barth syndrome, on an intermediate muscle-strength endpoint. Its larger trials in primary mitochondrial myopathy and dry AMD did not meet their primary endpoints, so the broad claims remain unestablished.
This article is educational and for the laboratory research community. Trulogic Labs products are sold for laboratory and research use only and are not for human consumption.